Gallo, P., & Tham, J. (2022). How NaProTechnology compares with assisted reproductive technology. Revista de Medicina y Ética, 33(1), 205-238. https://doi.org/10.36105/mye.2022v33n1.05
Gallo P, Tham J. How NaProTechnology compares with assisted reproductive technology. mye. 2022;33(1):205-238. doi:10.36105/mye.2022v33n1.05
Gallo, Pasquale, and Joseph Tham. "How NaProTechnology compares with assisted reproductive technology." Revista de Medicina y Ética, vol. 33, no. 1, 2022, pp. 205-238.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Authors argue NaProTechnology answers infertility better than ART
A 2022 position paper argues that NaProTechnology is a better solution to infertility than ART. The authors give ethical, medical, social, legal, and environmental reasons. They describe the risks and costs they attribute to ART and ask governments to support NaProTechnology.
Key Findings
The authors cite ART complications including ovarian hyperstimulation syndrome, placed at up to 30% of ART cycles, multiple pregnancies, and a cost above $12,000 per cycle in the USA.
The paper describes NaProTechnology as using Creighton Model FertilityCare charting to identify and treat correctable causes of infertility in men and women, with the aim of natural conception.
The paper reports a NaProTechnology series of 1072 couples treated from 1998 till 2002: approximately 40% of couples conceived, and among live births 4.6% were twins and 88% were to term.
The authors rate these outcomes as at least comparable to the best ART data and cite a Cochrane review that found too little data to show ART outperforms less intensive therapy.
The authors call on governments to promote and finance NaProTechnology and on medical and scientific societies to design studies comparing its success rate, costs, and complications with traditional ART.
Interpretation
The paper combines published figures on ART risks and NaProTechnology outcomes with ethical, religious, legal, and environmental arguments. Its ethical sections draw on Catholic teaching on marriage and procreation. The authors note that comparing success rates is hard because methods and study groups differ and no properly structured randomized controlled trials exist. They conclude that NaProTechnology can treat infertility with success rates apparently similar to ART, at lower risk and cost.
RRM Context
Restorative reproductive medicine identifies the underlying causes of infertility in both partners and treats them to restore the body's own function. NaProTechnology, developed by Dr. Thomas W. Hilgers, applies this principle through cycle charting, which allows evaluation and treatment to follow the individual cycle. IVF bypasses the reproductive system without establishing why conception is not occurring.
Our editorial summary of this paper, not the article's abstract.
Abstract
The progressive medicalisation of infertility in the last three decades has corresponded to an increasing diffusion of the Assisted Reproductive Technologies (ART) which have nearly completely concealed other more physiological, less risky, inexpensive and equally effective approaches to infertility. This paper tries to show how a systematic and integrated approach, such as NaProTechnology (NPT), which aims at optimising the physiological conditions in each menstrual cycle to allow a natural conception, seems to be a better solution for the treatment of infertility from ethical, medical, social, legal and environmental points of view. Governments should promote and finance NPT, and at the same time, medical and scientific societies should design studies to fairly compare NPT success rate, costs and complications to traditional ART.
RRM live-birth rates across 14 peer-reviewed cohorts, 11 countries, 2008-2026. Crude and adjusted-cumulative outcomes with follow-up windows, by condition and age group.
Clinician-reviewed comparison of fertility awareness-based methods (Billings, Creighton, Sensiplan, Marquette, Standard Days, apps). Every effectiveness figure cited and labeled by metric.